A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of the tyrosine kinase inhibitors (TKI) imatinib and/or sunitinib
A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of the tyrosine kinase inhibitors (TKI) imatinib and/or sunitinib. Connective Tissue Oncology Society Annual Meeting. 2008.